Advisors Asset Management Inc. Has $105,000 Position in Bio-Rad Laboratories Inc. (BIO)
Advisors Asset Management Inc. boosted its position in shares of Bio-Rad Laboratories Inc. (NYSE:BIO) by 22.3% during the second quarter, Holdings Channel reports. The firm owned 734 shares of the company’s stock after buying an additional 134 shares during the period. Advisors Asset Management Inc.’s holdings in Bio-Rad Laboratories were worth $105,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Emerald Acquisition Ltd. bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $61,903,000. First Trust Advisors LP raised its stake in shares of Bio-Rad Laboratories by 137.4% in the second quarter. First Trust Advisors LP now owns 113,660 shares of the company’s stock valued at $16,256,000 after buying an additional 65,785 shares during the last quarter. Hermes Investment Management Ltd. raised its stake in shares of Bio-Rad Laboratories by 35.3% in the second quarter. Hermes Investment Management Ltd. now owns 249,618 shares of the company’s stock valued at $35,700,000 after buying an additional 65,128 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Bio-Rad Laboratories by 77.8% in the first quarter. Renaissance Technologies LLC now owns 144,900 shares of the company’s stock valued at $19,811,000 after buying an additional 63,400 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Bio-Rad Laboratories by 37.1% in the first quarter. Goldman Sachs Group Inc. now owns 110,553 shares of the company’s stock valued at $15,115,000 after buying an additional 29,932 shares during the last quarter. Institutional investors and hedge funds own 62.83% of the company’s stock.
Bio-Rad Laboratories Inc. (NYSE:BIO) traded up 1.28% on Friday, hitting $163.27. 271,117 shares of the company’s stock traded hands. Bio-Rad Laboratories Inc. has a 12 month low of $122.03 and a 12 month high of $164.87. The stock has a market cap of $4.80 billion, a P/E ratio of 49.52 and a beta of 0.87. The stock has a 50 day moving average price of $157.47 and a 200-day moving average price of $147.16.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.61 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.52. Bio-Rad Laboratories had a net margin of 4.79% and a return on equity of 3.86%. The business had revenue of $516.80 million for the quarter, compared to analysts’ expectations of $497.80 million. During the same period in the previous year, the company earned $0.97 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that Bio-Rad Laboratories Inc. will post $3.10 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on BIO shares. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th. Jefferies Group lifted their target price on shares of Bio-Rad Laboratories from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, September 7th.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.